- Home
- INTS
as 07-26-2024 4:00pm EST
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | WESTPORT |
| Market Cap: | 64.9M | IPO Year: | 2023 |
| Target Price: | $12.00 | AVG Volume (30 days): | 11.7K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.01 - $11.44 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Intensity Therapeutics Inc. Common stock News
INTS Breaking Stock News: Dive into INTS Ticker-Specific Updates for Smart Investing
PR Newswire
17 days ago
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
Simply Wall St.
2 months ago
Will Intensity Therapeutics (NASDAQ:INTS) Spend Its Cash Wisely?
PR Newswire
2 months ago
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
MT Newswires
3 months ago
Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial
PR Newswire
3 months ago
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
PR Newswire
3 months ago
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR Newswire
4 months ago
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
GlobeNewswire
4 months ago
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Compare INTS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INTS Intensity Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.